ALK-2

General Information


DRACP ID  DRACP06066

Peptide Name   ALK-2

Sequence  CLKKLLKLLKKLLKLCLEHLLEHLEHLLEH

Sequence Length  30

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Cancer targeted peptides Membrane-targeted Targeted peptide conjugates



Activity Information


Hemolytic Activity  Mouse red blood cells:Hemolysis rate=5%=50μM

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic  Cyclic

Disulfide/Other Bond  Cys1<--->Cys16

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C170H294N44O39S2

Absent amino acids  ADFGIMNPQRSTVWY

Common amino acids  L

Mass  416010

Pl  8.81

Basic residues  10

Acidic residues  4

Hydrophobic residues  14

Net charge  6

Boman Index  -774

Hydrophobicity  26.67

Aliphatic Index  182

Half Life 
  Mammalian: 1.2 hour
  Yeast: >20 hour
  E.coli: >10 hour

Extinction Coefficient cystines  125

Absorbance 280nm  4.31

Polar residues  2

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID CN110862458A

Patent Title  Combined peptide with acid-activated anti-tumor activity and clinical application of combined peptide

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.